Hellenic Institute for the Study of Sepsis clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   PROMISE · ROLE OF PANCREATIC STONE PROTEIN (PSP) AND…PROMISE · ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 2026 to Oct 1, 2026

   Hellenic Institute for the Study of Sepsis·Phase 3· NCT07813767· Registry history of NCT07813767 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

2. Notable

   CLASSIFY · CLARITHROMYCIN TO PREVENT SECONDARY…CLASSIFY · CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS · SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

   Recruitment opened

   Hellenic Institute for the Study of Sepsis·Phase 3· NCT07834346· Registry history of NCT07834346 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.